Johnson & Johnson (NYSE:JNJ) EVP Sells 13,072 Shares of Company Stock

Johnson & Johnson (NYSE:JNJ) EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the sale, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. The trade was a 43.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Johnson & Johnson Stock Up 0.8%

NYSE:JNJ traded up $2.26 during trading hours on Friday, reaching $285.78. The company’s stock had a trading volume of 6,276,993 shares, compared to its average volume of 7,952,034. The company has a market cap of $687.95 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 2.77 and a beta of 0.22. Johnson & Johnson has a one year low of $193.55 and a one year high of $288.11. The business’s 50-day moving average is $266.83 and its 200-day moving average is $249.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period in the prior year, the business posted $2.80 earnings per share. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities research analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JNJ. New World Advisors LLC increased its position in Johnson & Johnson by 4.7% in the 3rd quarter. New World Advisors LLC now owns 4,935 shares of the company’s stock worth $1,306,000 after buying an additional 223 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of Johnson & Johnson by 7.4% in the third quarter. State Board of Administration of Florida Retirement System now owns 2,198,440 shares of the company’s stock valued at $582,015,000 after acquiring an additional 151,039 shares during the period. 49 Wealth Management LLC grew its stake in shares of Johnson & Johnson by 194.5% in the third quarter. 49 Wealth Management LLC now owns 5,705 shares of the company’s stock worth $1,510,000 after acquiring an additional 3,768 shares during the last quarter. Dock Street Asset Management Inc. grew its stake in shares of Johnson & Johnson by 2.5% in the third quarter. Dock Street Asset Management Inc. now owns 2,769 shares of the company’s stock worth $733,000 after acquiring an additional 67 shares during the last quarter. Finally, Insigneo Advisory Services LLC increased its position in Johnson & Johnson by 0.8% during the third quarter. Insigneo Advisory Services LLC now owns 22,762 shares of the company’s stock worth $6,026,000 after acquiring an additional 182 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several analyst reports. Evercore set a $300.00 target price on Johnson & Johnson in a report on Tuesday, October 20th. Morgan Stanley lowered their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a report on Thursday, October 15th. JPMorgan Chase & Co. increased their price target on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Tuesday, September 29th. Erste Group Bank lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Finally, TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Key Headlines Impacting Johnson & Johnson

Here are a few of the latest headlines about JNJ:

• Positive Sentiment: J&J is backing Francis Medical as it advances a water-vapor prostate-cancer treatment device toward FDA premarket approval. The investment expands its reach in minimally invasive oncology treatment. J&J leads Francis Medical investment to fund prostate cancer device
• Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The notice provides no specific findings, but litigation-related uncertainty may weigh on sentiment. Pomerantz Law Firm Investigates Claims on Behalf of Johnson & Johnson Investors

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.